Product Description
Nippon Kayaku was developing nk-012, an intravenous TOP Inhibitor,DNA Synthesis Inhibitor for advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01238952)
Mechanisms of Action: TOP Inhibitor, DNA Synthesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nippon Kayaku
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Triple Negative Breast Cancer|Small Cell Lung Cancer|Colorectal Cancer|Multiple Myeloma
Phase 1: Colorectal Cancer|Triple Negative Breast Cancer|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01238939 |
A6012113US | P1 |
Completed |
Colorectal Cancer |
2013-12-01 |
2019-03-19 |
Treatments |
|
NCT01238952 |
A6012121US | P1 |
Completed |
Triple Negative Breast Cancer |
2010-11-01 |
2019-03-19 |
Treatments |
|
NCT00542958 |
N06-10089 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-04-01 |
2019-03-21 |
Treatments |
|
NCT00951054 |
A6012211US | P2 |
Completed |
Triple Negative Breast Cancer |
2014-12-01 |
2019-03-18 |
Treatments |
|
JapicCTI-111652 |
JapicCTI-111652 | P2 |
Completed |
Multiple Myeloma |
2014-09-01 |
|||
NCT00951613 |
A6012212US | P2 |
Completed |
Small Cell Lung Cancer |
2012-01-01 |
2019-03-18 |
Treatments |
|
JapicCTI-090780 |
JapicCTI-090780 | P2 |
Completed |
Colorectal Cancer |
None |
Recent News Events
Date |
Type |
Title |
|---|